Estimating tuberculosis cases and their economic costs averted in the United States over the past two decades
Estimating tuberculosis cases and their economic costs averted in the United States over the past two decades
复制标题
DOI：
10.5588/ijtld.15.1001
复制
发表时间：
2016-07-01
影响因子：
4
通讯作者：
LoBue, P. A.
中科院分区：
文献类型：
--
作者：
Castro, K. G.;Marks, S. M.;LoBue, P. A.
背景技术背景：在20世纪80年代后期，美国对结核病（TB）的重新抬头采取了协调一致的公共卫生对策，结核病的年发病率大幅下降。方法：对1995-2014年美国避免的结核病病例进行了估计：情景1使用1992年的静态病例率;情景2将1992年的外国出生病例率应用于外国出生病例，并将美国出生病例的年下降率应用于复苏前的5.1%;和统计模型评估人类免疫缺陷病毒和结核病规划指数。我们应用疾病成本来估计2014年美元的社会效益（避免的成本）。结果：在1992-2014年期间，报告了368184例结核病病例，在此期间病例减少了三分之二。在情景和统计模型中，1995-2014年期间避免的结核病例约为145 000至319 000例。避免的结核病病例的社会效益范围从3.1美元到67亿美元，不包括死亡，从6.7美元到14.5亿美元，包括deaths.CONCLUSIONS：在美国结核病控制和预防的协调努力产生了显着数量的结核病病例避免和社会经济效益。我们说明了协调一致的行动和有针对性的公共卫生资金的价值。
BACKGROUND: Following a concerted public health response to the resurgence of tuberculosis (TB) in the United States in the late 1980s, annual TB incidence decreased substantially. However, no estimates exist of the number and cost savings of TB cases averted.METHODS: TB cases averted in the United States during 1995-2014 were estimated: Scenario 1 used a static 1992 case rate; Scenario 2 applied the 1992 rate to foreign-born cases, and a pre-resurgence 5.1% annual decline to US-born cases; and a statistical model assessed human immunodeficiency virus and TB program indices. We applied the cost of illness to estimate the societal benefits (costs averted) in 2014 dollars.RESULTS: During 1992-2014, 368 184 incident TB cases were reported, and cases decreased by two thirds during that period. In the scenarios and statistical model, TB cases averted during 1995-2014 ranged from approximately 145 000 to 319 000. The societal benefits of averted TB cases ranged from US$3.1 to US$6.7 billion, excluding deaths, and from US$6.7 to US$14.5 billion, including deaths.CONCLUSIONS: Coordinated efforts in TB control and prevention in the United States yielded a remarkable number of TB cases averted and societal economic benefits. We illustrate the value of concerted action and targeted public health funding.